Consolidated income statement

January 1 – June 30

millions of CHF	Notes	2022	2021 1)
Continuing operations
Sales from continuing operations	3	1’516.8	1’495.0
Cost of goods sold		–1’085.9	–1’048.4
Gross profit from continuing operations		430.9	446.6
Selling and distribution expenses		–158.4	–153.4
General and administrative expenses		–188.1	–172.3
Research and development expenses		–32.4	–30.5
Net impairment loss on contract assets and trade accounts receivable	2	–36.8	–2.6
Other operating income / (expenses), net	8	–40.6	9.6
Operating income (EBIT) from continuing operations		–25.5	97.4
Interest and securities income	9	3.5	5.1
Interest expenses	9	–13.2	–12.4
Other financial income / (expenses), net	9	18.3	–2.1
Share of gains / (losses) of associates		–1.4	–1.1
Income before income tax expenses from continuing operations		–18.3	86.9
Income tax expenses	10	–30.5	–26.2
Net income from continuing operations		–48.8	60.8
Net income from discontinued operations, net of tax	6	–	25.6
Net income		–48.8	86.3
– thereof attributable to shareholders of Sulzer Ltd		–48.3	85.7
– thereof attributable to non-controlling interests		–0.5	0.7

Earnings per share (in CHF)
Basic earnings per share		–1.43	2.53
Diluted earnings per share		–1.41	2.51

Earnings per share from continuing operations (in CHF)
Basic earnings per share from continuing operations		–1.43	1.78
Diluted earnings per share from continuing operations		–1.41	1.76

Due to rounding, numbers presented may not add up to the totals provided.

1) Comparative information has been re-presented due to discontinued operations (details are described in note 6). Net impairment loss on contract assets and trade accounts receivable was previously included in selling and distribution expenses.

Business review Chemtech

Consolidated statement of comprehensive income